← ANALYST RATINGS · TIPRANKS
Viking Therapeutics (VKTX): analyst forecast and price target
Price targets and ratings of
Analyst consensus
Strong Buy17 Buy1 Hold0 Sell
Ratings of 18 analysts in the last 3 months12-month forecast
$92.18+266.2% upside
Based on 18 price targets given in the last 3 months, the average target is $92.18, the highest $125, the lowest $38.00. The average is +266.2% from the last price of $25.17.
Highest target $125
Average target $92.18
Lowest target $38.00
Analyst ratings 25
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $27.00 → $29.00+7.4% | Hold | +15.2% | Reiterated | 16.10.26on TipRanks 18:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $26.00 → $28.00+7.7% | Hold | +11.2% | Reiterated | 16.10.26on TipRanks 18:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $26.00 → $28.00+7.7% | Hold | +11.2% | Reiterated | 16.10.26on TipRanks 18:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $26.00 → $28.00+7.7% | Hold | +11.2% | Reiterated | 16.10.26on TipRanks 18:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $28.00 → $30.00+7.1% | Buy | +19.2% | Reiterated | 16.10.26on TipRanks 18:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $27.00 → $29.00+7.4% | Hold | +15.2% | Reiterated | 16.10.26on TipRanks 18:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $28.00 → $27.00−3.6% | Hold | +7.3% | Reiterated | 15.10.26on TipRanks 13:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $27.00 → $26.00−3.7% | Hold | +3.3% | Reiterated | 15.10.26on TipRanks 13:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $28.00 → $26.00−7.1% | Hold | +3.3% | Reiterated | 15.10.26on TipRanks 13:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $27.00 → $26.00−3.7% | Hold | +3.3% | Reiterated | 15.10.26on TipRanks 13:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $29.00 → $28.00−3.4% | Buy | +11.2% | Reiterated | 15.10.26on TipRanks 13:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $28.00 → $27.00−3.6% | Hold | +7.3% | Reiterated | 15.10.26on TipRanks 13:05 | — | |
| Edward Nash★★★★★★★★★★#204 · hits 52% · avg +29.5% | Canaccord Genuity | $114 | Buy | +352.9% | Reiterated | 14.10.26on TipRanks Oct 15 07:30 | −3.3%next day +7.2% | ↗ |
| Unknown Analyst | UBS | $94.00 | Buy | +273.5% | Initiated | 14.10.26on TipRanks Oct 15 07:30 | −3.3%next day +7.2% | ↗ |
| Joseph Pantginis★★★★★★★★★★#243 · hits 55% · avg +24.8% | H.C. Wainwright | $102 | Buy | +305.2% | Reiterated | 14.10.26on TipRanks 10:50 | −3.3%next day +7.2% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $30.00 → $28.00−6.7% | Hold | +11.2% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $29.00 → $27.00−6.9% | Hold | +7.3% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $30.00 → $28.00−6.7% | Hold | +11.2% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $29.00 → $27.00−6.9% | Hold | +7.3% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $31.00 → $29.00−6.5% | Buy | +15.2% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $30.00 → $28.00−6.7% | Hold | +11.2% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $29.00 → $30.00+3.4% | Hold | +19.2% | Reiterated | 11.10.26on TipRanks 16:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $28.00 → $29.00+3.6% | Hold | +15.2% | Reiterated | 11.10.26on TipRanks 16:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $29.00 → $30.00+3.4% | Hold | +19.2% | Reiterated | 11.10.26on TipRanks 16:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $28.00 → $29.00+3.6% | Hold | +15.2% | Reiterated | 11.10.26on TipRanks 16:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $29.00 → $30.00+3.4% | Hold | +19.2% | Reiterated | 11.10.26on TipRanks 16:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $30.00 → $29.00−3.3% | Hold | +15.2% | Reiterated | 09.10.26on TipRanks 07:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $29.00 → $28.00−3.4% | Hold | +11.2% | Reiterated | 09.10.26on TipRanks 07:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $30.00 → $29.00−3.3% | Hold | +15.2% | Reiterated | 09.10.26on TipRanks 07:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $29.00 → $28.00−3.4% | Hold | +11.2% | Reiterated | 09.10.26on TipRanks 07:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $30.00 → $29.00−3.3% | Hold | +15.2% | Reiterated | 09.10.26on TipRanks 07:05 | — | |
| Gregory Renza★★★★★★★★★★#373 · hits 55% · avg +18.8% | Truist Financial | $87.00 → $85.00−2.3% | Buy | +237.7% | Reiterated | 07.10.26on TipRanks 09:10 | +0.8%next day −2.4% · 5 days −9.8% | ↗ |
| Edward Nash★★★★★★★★★★#204 · hits 52% · avg +29.5% | Canaccord Genuity | $114 | Buy | +352.9% | Reiterated | 07.10.26on TipRanks 07:11 | +0.8%next day −2.4% · 5 days −9.8% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $38.00 → $30.00−21.1% | Hold | +19.2% | Reiterated | 07.10.26on TipRanks 01:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $36.00 → $29.00−19.4% | Hold | +15.2% | Reiterated | 07.10.26on TipRanks 01:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $37.00 → $30.00−18.9% | Hold | +19.2% | Reiterated | 07.10.26on TipRanks 01:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $36.00 → $29.00−19.4% | Hold | +15.2% | Reiterated | 07.10.26on TipRanks 01:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $39.00 → $31.00−20.5% | Buy | +23.2% | Reiterated | 07.10.26on TipRanks 01:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $38.00 → $30.00−21.1% | Hold | +19.2% | Reiterated | 07.10.26on TipRanks 01:05 | — | |
| Naz Rahman★★★★★★★★★★#12198 · hits 36% · avg −7.5% | Maxim Group | $70.00 | Buy | +178.1% | Reiterated | 06.10.26on TipRanks Oct 7 11:15 | −3.6%next day +0.8% · 5 days −6.0% | ↗ |
| Michael Ulz★★★★★★★★★★#6183 · hits 43% · avg +0.9% | Morgan Stanley | $95.00 | Buy | +277.4% | Reiterated | 06.10.26on TipRanks Oct 7 06:15 | −3.6%next day +0.8% · 5 days −6.0% | ↗ |
| Joseph Pantginis★★★★★★★★★★#243 · hits 55% · avg +24.8% | H.C. Wainwright | $102 | Buy | +305.2% | Reiterated | 06.10.26on TipRanks 10:05 | −3.6%next day +0.8% · 5 days −6.0% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $40.00 → $38.00−5.0% | Hold | +51.0% | Reiterated | 29.09.26on TipRanks Sep 28 23:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $38.00 → $36.00−5.3% | Hold | +43.0% | Reiterated | 29.09.26on TipRanks Sep 28 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $38.00 → $37.00−2.6% | Hold | +47.0% | Reiterated | 29.09.26on TipRanks Sep 28 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $38.00 → $36.00−5.3% | Hold | +43.0% | Reiterated | 29.09.26on TipRanks Sep 28 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $41.00 → $39.00−4.9% | Buy | +54.9% | Reiterated | 29.09.26on TipRanks Sep 28 23:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $39.00 → $38.00−2.6% | Hold | +51.0% | Reiterated | 29.09.26on TipRanks Sep 28 23:05 | — | |
| William Wood★★★★★★★★★★#3198 · hits 53% · avg +11.7% | B. Riley Securities | $85.00 | Buy | +237.7% | Reiterated | 23.09.26on TipRanks Sep 25 04:30 | +2.7%next day −11.7% · 5 days −21.1% | ↗ |
| Naz Rahman★★★★★★★★★★#12198 · hits 36% · avg −7.5% | Maxim Group | $70.00 | Buy | +178.1% | Reiterated | 23.09.26on TipRanks 15:06 | +2.7%next day −11.7% · 5 days −21.1% | ↗ |
| Unknown Analyst | Leerink Partners | $118 | Buy | +368.8% | Reiterated | 23.09.26on TipRanks 09:55 | +2.7%next day −11.7% · 5 days −21.1% | ↗ |
| Roger Song★★★★★★★★★★#4779 · hits 41% · avg +2.6% | Jefferies | $101 | Buy | +301.3% | Reiterated | 23.09.26on TipRanks 09:45 | +2.7%next day −11.7% · 5 days −21.1% | ↗ |
| Daniel Brims★★★★★★★★★★#12312 · hits 19% · avg −36.9% | Lake Street | $89.00 | Buy | +253.6% | Reiterated | 23.09.26on TipRanks 09:10 | +2.7%next day −11.7% · 5 days −21.1% | ↗ |
| Edward Nash★★★★★★★★★★#204 · hits 52% · avg +29.5% | Canaccord Genuity | $114 | Buy | +352.9% | Reiterated | 23.09.26on TipRanks 07:15 | +2.7%next day −11.7% · 5 days −21.1% | ↗ |
| Gregory Renza★★★★★★★★★★#373 · hits 55% · avg +18.8% | Truist Financial | $83.00 → $87.00+4.8% | Buy | +245.6% | Reiterated | 23.09.26on TipRanks Sep 22 10:55 | +35.7%next day +2.7% · 5 days −20.9% | ↗ |
| Richard Law CFA★★★★★★★★★★#3237 · hits 50% · avg +9.1% | Goldman Sachs | $35.00 → $38.00+8.6% | Hold | +51.0% | Reiterated | 22.09.26on TipRanks Sep 23 08:45 | +35.7%next day +2.7% · 5 days −20.9% | ↗ |
| Annabel Samimy★★★★★★★★★★#421 · hits 51% · avg +19.3% | Stifel Nicolaus | $30.00 → $95.00+216.7% | Buy | +277.4% | Reiterated | 22.09.26on TipRanks Sep 23 06:05 | +35.7%next day +2.7% · 5 days −20.9% | ↗ |
| Jeet Mukherjee★★★★★★★★★★#655 · hits 63% · avg +26.2% | BTIG | $125 | Buy | +396.6% | Reiterated | 22.09.26on TipRanks Sep 23 05:55 | +35.7%next day +2.7% · 5 days −20.9% | ↗ |
| Jay Olson★★★★★★★★★★#301 · hits 48% · avg +24.9% | Oppenheimer | $100 → $120+20.0% | Buy | +376.8% | Assigned | 22.09.26on TipRanks 12:50 | +35.7%next day +2.7% · 5 days −20.9% | ↗ |
| Andy Hsieh★★★★★★★★★★#1805 · hits 48% · avg +9.0% | William Blair | — | Buy | — | Reiterated | 22.09.26on TipRanks 12:05 | +35.7%next day +2.7% · 5 days −20.9% | ↗ |
| Michael Ulz★★★★★★★★★★#6183 · hits 43% · avg +0.9% | Morgan Stanley | $95.00 | Buy | +277.4% | Reiterated | 22.09.26on TipRanks 10:55 | +35.7%next day +2.7% · 5 days −20.9% | ↗ |
| Steven Seedhouse★★★★★★★★★★#1374 · hits 43% · avg +10.3% | Cantor Fitzgerald | $100 | Buy | +297.3% | Reiterated | 14.08.26on TipRanks 10:05 | +1.0%next day +1.8% · 5 days +3.5% | ↗ |
| Hardik Parikh★★★★★★★★★★#11483 · hits 28% · avg −12.1% | J.P. Morgan | $75.00 → $65.00−13.3% | Buy | +158.2% | Reiterated | 11.08.26on TipRanks 07:40 | −1.5%next day +0.4% · 5 days −0.9% | ↗ |
| Biren Amin★★★★★★★★★★#1671 · hits 46% · avg +7.6% | Piper Sandler | $71.00 | Buy | +182.1% | Reiterated | 30.07.26on TipRanks 06:56 | −2.6%next day −4.9% · 5 days −3.0% | ↗ |
| Ryan Deschner★★★★★★★★★★#506 · hits 69% · avg +41.7% | Raymond James | — | Buy | — | Reiterated | 24.06.26on TipRanks 11:05 | +8.8%next day −2.5% · 5 days −2.7% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Viking Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 06.10.26: target $92.19 at a price of $29.28 (+214.8%); now: $92.18 at $25.17 (+266.2%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 16 | 23 | 21 | 29 | 24 |
| Buy | 3 | 4 | 5 | 5 | 3 | 1 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 28.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.06 (from $-1.38 to $-0.66). Last quarter: $-1.10.
Best top-analyst consensus in the sector · Healthcare
About Viking Therapeutics
- CEO: Brian Lian
- Employees: 65
- 9920 Pacific Heights Boulevard, San Diego, CA, 92121, US
- www.vikingtherapeutics.com
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
Data from the stock’s TipRanks forecast page, read 25 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗